Endo to divest its American Medical Systems men's and prostate businesses to Boston Scientific
Ireland-headquartered Endo International (Nasdaq: ENDP) has entered into a definitive agreement with Boston Scientific (NYSE: BSX) under which Boston will acquire the men’s and prostate health businesses belonging to Endo's American Medical Systems for up to $1.65 billion.
Of that sum, $1.6 billion will be paid in cash upon closing. Endo is also eligible to receive a milestone payment of $50 million in cash conditioned on Boston Scientific achieving certain product revenue milestones in the men’s health and prostate health businesses in 2016. The companies expect to close the transaction in the third quarter of 2015, subject to customary conditions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze